Drug guidance
Liposomal irinotecan for first-line treatment of metastatic adenocarcinoma of the pancreas
Condition
Cancer
Gastrointestinal tract
1 July 2026
-
Published on 01 Jul 2026
Last Updated on 01 Jul 2026
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended liposomal irinotecan in combination with oxaliplatin, fluorouracil and leucovorin for inclusion on the MOH List of Subsidised Drugs for first-line treatment of metastatic adenocarcinoma of the pancreas. The decision was based on the uncertain extent of clinical benefit, unfavourable cost effectiveness compared with existing treatment alternatives, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claims eligibility for liposomal irinotecan are provided in the Annex.